Action 9939 KINTOR PHARMACEUTICAL LIMITED
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Kintor Pharmaceutical Limited

Actions

9939

KYG5273B1077

Marché Fermé - Hong Kong S.E.
Autres places de cotation
 10:09:05 07/06/2024 		Varia. 5j. Varia. 1 janv.
1,22 HKD 0,00 % Graphique intraday de Kintor Pharmaceutical Limited +0,83 % -25,15 %
04/06 Kintor Pharma reçoit le nom de l'ingrédient cosmétique standard pour le produit KX-826 MT
24/05 Le médicament de Kintor Pharmaceutical contre l'alopécie androgénique reçoit le feu vert des autorités réglementaires ; le cours de l'action bondit de 10%. MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Kintor Pharma Receives Standard Cosmetic Ingredient Name for KX-826 Product
Kintor Pharmaceutical's Androgenic Alopecia Drug Gets Regulatory Nod; Share Prices Shoot 10%
Kintor Pharmaceutical Limited Announces That the Clinical Trial of Its In-House Developed and Potential First-In-Class Kx-826 Tincture 1.0% for the Treatment of Male Adult Androgenetic Alopecia ("Aga") in China (The "Clinical Trial") Was Cleared by the National Medical Products Administration (The "Nmpa") Recently
Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint
Kintor Pharmaceutical Concludes Phase II Clinical Trial for Androgenic Alopecia Treatment
Kintor Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023
Kintor Pharmaceutical's Trial of Androgenetic Alopecia Drug Cleared by Chinese Regulator
Kintor Pharmaceutical Limited Announces Phase Ib/III Clinical Trial of KX-826 and Minoxidil Combination Therapy for the Treatment of Men Adults Receives Clearance by China NMPA
Kintor Pharmaceutical's Phase 3 Trial for Alopecia Treatment Promotes Hair Growth; Shares Plunge 30%
Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia
Kintor Pharmaceutical : Pharma Announces Publication of Phase Ib/II Data from GT90001 and Nivolumab Combination Therapy for Advanced HCC in BMC Medicine
Kintor Pharmaceutical Limited Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China
Kintor Pharmaceutical : Pharma Announces the Approval of Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China
Kintor Pharmaceutical : Pharma Announces 2023 Interim Results and Recent Business Highlights
Kintor Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2023
Kintor Pharmaceutical Completes Enrollment for Alopecia Drug Trial
Kintor Pharma Announces Completion of Patient Enrollment in Phase Ii Clinical Trial of Gt20029 for Treatment of Androgenetic Alopecia in China
Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA
Kintor Pharmaceutical Enrolls First Patient for Phase III of Alopecia Drug Trial
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 9939
  4. Actualités Kintor Pharmaceutical Limited
  5. Autres langues